跳至主要内容
临床试验/NCT05666570
NCT05666570撤回不适用

A Study to Demonstrate the Safety and Performance of the Avelle® Negative Pressure Wound Therapy System on Chronic Wounds

ConvaTec Inc.1 个研究点 分布在 1 个国家目标入组 59 人开始时间: 2022年5月18日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
ConvaTec Inc.
入组人数
59
试验地点
1
主要终点
The reduction in wound size of the target wound between baseline and end of study

研究概览

简要总结

This study seeks to demonstrate the performance of Negative Pressure Wound Therapy on chronic wounds such as diabetic foot ulcers and venous leg ulcers.

详细描述

This study seeks to demonstrate the performance of Negative Pressure Wound Therapy on chronic wounds such as diabetic foot ulcers and venous leg ulcers. The primary objective of the study is to demonstrate the performance and safety of Avelle Negative Pressure Wound Therapy on wound and wound fluid management when used in accordance with the instructions for use.

Participation in the study is anticipated to be two weeks. The Avelle™ NPWT System will be used for two weeks and participants will be seen for study visits during this time. Study participants will need to visit the doctor's office up to five times and, at a minimum, will be required to see the health care provider three times, dependent on the condition of the wound. Each visit is anticipated to last for approximately 45 to 60 minutes.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Venous insufficiency as defined by CEAP Classification of C6 or C6R or Diabetic foot ulcer
  • Stalled wound/failed treatment in the opinion of the investigator. Defined as a wound that has not progressed by more than 30% in the previous 4 weeks
  • 1 qualifying wound which is amenable to NPWT
  • Reliable and available for follow-up
  • Low to moderate exudate
  • Able to tolerate negative pressure
  • >18 years old at the time of consent
  • Able and willing to provide informed consent

排除标准

  • Known sensitivities or allergies to components of the Avelle™ Negative Pressure Wound Therapy System
  • Necrotic wounds or wounds with eschar present
  • Wound is too small or too large based on wound dressing (> 1cm2 and < 100cm2)
  • Wound depth >2cm
  • Use of DuoDERM® gel /petroleum gel/ creams/oil-based products
  • Active treatment for cancer or completed within the last 3 months
  • Severe malnutrition in the opinion of the investigator
  • Visible bone/tendon or exposed articular capsule
  • Exposed blood vessels
  • Clotting disorder
  • Malignant wounds
  • Systemic infection
  • Untreated osteomyelitis
  • Patients with HbA1c greater than 9 on Day 0 (Test to be performed within last 3 months)
  • Wounds greater than 12 months old
  • Previous failed NPWT within last 6 weeks on the qualifying wound
  • Active Pregnancy
  • Chronic Kidney Disease score of 5

结局指标

主要结局

The reduction in wound size of the target wound between baseline and end of study

时间窗: 14 days

Area reduction will be assessed by measuring the wound area at Day 0, Day 6 (+/- 1 day), and Day 7 (+/- 1 day)

次要结局

  • Wound Healing Status(14 days)
  • Assessment of Skin(14 Days)
  • Rate of Device Related Adverse Events(14 days)

研究者

发起方
ConvaTec Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

The Avelle® Negative Pressure Wound Therapy System... | 临床试验